@article{Mehta2024-mq,

title = {One-year anti-VEGF therapy outcomes in diabetic macular edema 

 based on treatment intensity: Data from the Fight Retinal 

 Blindness! Registry},

author = {Hemal Mehta and Pierre-Henry Gabrielle and Yohei Hashimoto and Getiye Dejenu Kibret and Jennifer Arnold and Tremeur Guillaumie and Wajiha Jurdi Kheir and Gerhard Kok and Stela Vujosevic and Louise O'Toole and Els Mangelschots and Nandor Jaross and Lala Ceklic and Vincent Daien and Francesco Viola and David Squirrell and Francisco Javier Lavid and Catherine Creuzot-Garcher and Daniel Barthelmes and Mark Gillies and Fight Retinal Blindness! Study Group},

year  = {2024},

date = {2024-09-01},

journal = {Ophthalmol. Retina},

volume = {8},

number = {9},

pages = {872–879},

publisher = {Elsevier BV},

abstract = {PURPOSE: To compare one-year outcomes of eyes with diabetic 

 macular edema (DME) treated in routine clinical practice based 

 on the proportion of visits where intravitreal vascular 

 endothelial growth factor (VEGF) inhibitor injections were 

 delivered. DESIGN: Cohort study PARTICIPANTS: There were 2288 

 treatment-naïve eyes with DME starting intravitreal VEGF 

 inhibitor therapy from 31 October 2015 to 31 October 2021 from 

 the Fight Retinal Blindness! international outcomes registry. 

 METHODS: Eyes were grouped according to the proportion of visits 

 at which an injection was received, Group A with less than the median of 67% (n=1172) versus Group B with greater than the median (n=1116). MAIN OUTCOME MEASURE: Mean visual acuity (VA) 

 change after 12 months of treatment. RESULTS: The mean (95% 

 confidence interval [CI]) VA change after 12 months of treatment 

 was 3.6 (2.8, 4.4) letters for eyes in Group A versus 5.2 (4.4, 5.9) letters for eyes in Group B (p=0.005). The mean (95% CI) 

 central subfield thickness (CST) change was -69 (-76, -61) 

 μm and -85 (-92, -78) μm for eyes in Group A versus Group B, respectively (p=0.002). A moderate positive correlation 

 was observed between the number of injections received over 12 

 months of treatment and the change in VA (p<0.001). 

 Additionally, eyes that received more injections had a 

 moderately greater CST reduction. CONCLUSIONS: This registry 

 analysis found that overall VA and anatomic outcomes tended to 

 be better in DME eyes treated at a greater proportion of visits 

 in the first year of intravitreal VEGF inhibitor therapy.},

keywords = {Anti-VEGF; Diabetic macular edema; Pro re nata; Real-world   evidence; Treat-and-extend},

pubstate = {published},

tppubtype = {article}

}